Gilead Sciences (GILD -1.3%) says Phase 3 clinical trial results from its study comparing single...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD -1.3%) says Phase 3 clinical trial results from its study comparing single tablet regimens of Complera versus Atripla in adults with HIV infection demonstrated that Complera - which is marketed as Eviplera in the E.U. - showed a statistically significant difference in efficacy compared to Atripla among patients with low baseline viral load, and was non-inferior to Atripla among patients with high baseline viral load. Separately, the company also reports that two-year results from two Phase 3 tests of it's newest single tablet HIV regimen, Stribild, also showed it was non-inferior after two years of treatment as compared to two other standard HIV regimens.